Evaluation of sialidase NEU3 effect on cell viability with or without gefitinib. Matilde Forcella Monica Oldani Samantha Epistolio Stefania Freguia Eugenio Monti Paola Fusi Milo Frattini 10.1371/journal.pone.0187289.g004 https://plos.figshare.com/articles/figure/Evaluation_of_sialidase_NEU3_effect_on_cell_viability_with_or_without_gefitinib_/5557231 <p>MTT test was performed on HSAEC1, HCC4006 and H1734 cell lines transfected with either the empty vector (mock) or pcDNA3.1-HsNEU3 and then treated or not with 27 nM or 1 μM gefitinib for 36 h <i>post</i>-transfection. Data were normalized on control cells transfected with the empty vector (A). Cell viabilities of mock and NEU3 transfected cells are reported after treatment with either 27 nM (B) or 1 μM gefitinib (C). Data were normalized on control cells without drug. Values are presented as means ± standard error (SE).</p> 2017-10-31 17:47:15 therapies sensitivity NSCLC cell viability NEU 3 EGFR point mutations TKI Non-Small Cell Lung Cancer Akt pathway NEU 3 overexpressing patients ERK pathway lung cancer cell lines plasma membrane-associated NEU 3 Adenocarcinoma sialidase NEU 3 EGFR pathways activation NEU 3 overexpression mucosa cell line Non-small cell lung cancer sialidase NEU 3 overexpression EGFR wild-type gene sequence